Le Lézard
Classified in: Health
Subjects: EXE, RCL, PSF

Advisory - Unauthorized "Smart Brain Formulations Serotonin Support" may pose serious health risks


OTTAWA, Dec. 1, 2017 /CNW/ -

Issue
Health Canada is advising Canadians that the unauthorized health product "Smart Brain Formulations Serotonin Support" may pose serious health risks. The product is labelled to contain lithium orotate, which is a prescription drug and should be used only under the supervision of a health care professional. Health Canada testing also found bacterial contamination with E. coli, which can cause serious health problems. The product was being offered for sale by the company Robert Lamberton Consulting, by email. The company currently does not hold a site licence or any product licences with Health Canada.

Who is affected

Affected products

What consumers should do

Background
Lithium is a prescription drug and is approved for treatment of manic episodes of manic-depressive illness. Common lithium side effects include increased thirst and urination, hand tremors and drowsiness. Severe dehydration has been reported. Intoxication can occur, especially when taken with other medications. Symptoms of intoxication can include vomiting, diarrhea, muscle twitches and lethargy. Patients should take lithium only after receiving a diagnosis and prescription from a health care professional. Otherwise, patients risk inappropriate treatment for their condition and harmful drug interactions or side effects.

E. coli are bacteria that live naturally in the intestines of some animals, and can be found in their feces. People infected with E. coli can have a wide range of symptoms. Common symptoms of E. coli can appear within one to ten days after contact with the bacteria, and include severe stomach cramps, profuse watery or bloody diarrhea, vomiting, nausea and headache. Young children aged 5 and under, older adults, and people with weakened immune systems are more likely to get sick and their symptoms may be more severe.

What Health Canada is doing
Health Canada is following up and will take further compliance and enforcement action as necessary. If additional retailers or distributors of these products are identified, Health Canada will take appropriate action and inform Canadians.

Related Links:

For more information
Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.

To learn more about natural health products and other self-care products, visit Canada.ca/selfcare-products.

 

Également disponible en français

 

SOURCE Health Canada


These press releases may also interest you

at 05:25
PureTech Health plc ("PureTech" or the "Company") today announces its results for the year ended December 31, 2023, as well as its cash balance as of the first quarter ended March 31, 2024. The following information represents select highlights from...

at 05:11
Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost...

at 04:31
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CHINA, HONG KONG, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR...

at 04:30
The Balance RehabClinic, renowned for its luxury mental health and addiction services, proudly announces its expansion into The Balance Healthcare Group: a collection of premium mental health solutions tailored for affluent individuals. These new...

at 03:47
Zest Dental Solutions, a global leader in innovative dental solutions proudly announces a strategic partnership with The Pathway. Founded by Justin Moody, DDS and based in Arizona, The Pathway is a continuing education program that teaches dentists...

at 03:34
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...



News published on and distributed by: